Every 8-K that XBiotech Inc (XBIT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow XBIT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XBIT filings page.
XBiotech Inc., a British Columbia, Canada corporation listed on the NASDAQ Global Select Market under the symbol XBIT, submitted an amended current report to clarify previously described background information for one of its directors. The update concerns how Craig Rademaker’s role with private equity firms is characterized.
The company now states that Mr. Rademaker is a consultant to a number of Canadian private equity firms and that his responsibilities principally include capital markets activities. No changes to his directorship, compensation, or company financials are discussed in this update.
XBiotech Inc. has entered into a new Executive Employment Agreement with its CEO and President, John Simard, effective October 1, 2025, replacing all prior arrangements. The agreement, approved by the Compensation Committee of independent directors, formalizes his pay structure and is intended to recognize his past and ongoing contributions and support leadership continuity and any future transition.
Under the agreement, Mr. Simard’s annual base salary remains at USD $1,250,000, and he is eligible for an annual base bonus of USD $4,530,442.00, reflecting his average bonus over the past five years, with actual amounts set each year by the committee and both salary and bonus adjusted annually for inflation. On retirement, disability, or termination without cause, he or his estate is entitled to a cash severance equal to three full calendar years of base salary and three full calendar years of base bonus, paid after execution of a release, and on retirement he will also serve as a consultant for at least 18 months while continuing to receive base salary. Severance is reduced in the event of termination for cause as described in the agreement.
XBiotech Inc. held its annual stockholder meeting on August 29, 2025, where all management-backed proposals were approved. Stockholders elected five directors: John Simard, Thomas Kündig, Craig Rademaker, Tevi D. Troy and David Soffer, each receiving over 12.3 million votes in favor or abstentions only.
Stockholders ratified Whitley Penn LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025, with 15,206,712 votes for and 413,673 against. They also approved, on an advisory basis, executive compensation and approved the Company’s 2025 Equity Incentive Plan, each with more than 11.9 million votes in favor.
XBiotech announced two significant appointments to its Board of Directors on June 24, 2025. The company has appointed Dr. Thomas Kündig and Craig Rademaker as new board members, with immediate effect until the 2025 Annual General Meeting.
Key appointments and roles:
- Dr. Kündig, Director of Dermatology at University Hospital Zurich, joins the Compensation Committee. He brings expertise in immunodermatology and pioneering work in intralymphatic immunotherapy (ILIT)
- Mr. Rademaker, a financial industry veteran with 25+ years experience, joins the Audit Committee. He currently leads a Private Equity firm managing assets over $5 billion
The updated committee structure now includes:
- Audit Committee: Jan-Paul Waldin, Dr. Peter Libby, and Craig Rademaker
- Compensation Committee: Jan-Paul Waldin, Dr. Peter Libby, and Dr. Thomas Kündig